Kanada - angličtina - Health Canada

aventis pasteur limited - tetanus toxoid adsorbed - liquid - 5lf - tetanus toxoid adsorbed 5lf - toxoids

Kanada - angličtina - Health Canada

aventis pasteur limited - diphtheria toxoid adsorbed; tetanus toxoid adsorbed - liquid - 25lf; 5lf - diphtheria toxoid adsorbed 25lf; tetanus toxoid adsorbed 5lf - toxoids

Kanada - angličtina - Health Canada

iaf biovac inc. - diphtheria toxoid; tetanus toxoid - suspension - 2lf; 5lf - diphtheria toxoid 2lf; tetanus toxoid 5lf - toxoids

Kanada - angličtina - Health Canada

lederle labs, division of american cyanamid co - tetanus toxoid; diphtheria toxoid - suspension - 5lf; 2lf - tetanus toxoid 5lf; diphtheria toxoid 2lf - toxoids

Spojené státy - angličtina - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (unii: 8c367iy4ey) (bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) - unii:8c367iy4ey), bordetella pertussis pertactin antigen (formaldehyde inactivated) (unii: i05o535nv6) (bordetella pertussis pertactin antigen (formaldehyde inactivated) - unii:i05o535nv6), bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (unii: qsn5xo8zsu) (bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) - unii:qsn5xo8zsu), poliovirus type 1 antigen (formaldehyde inactivated) (unii: 0lvy784c09) (poliovirus type 1 antigen (formaldehyde inactivated) - unii:0lvy784c09), poliovirus type 2 antigen (formaldehyde inactivated) (unii: 23je9kdf4r) (poliovirus type 2 antigen (formaldehyde inactivated) - unii:23je9kdf4r), poliovirus type 3 antigen (formaldehyde inactivated) (unii: 459rom8m9m) (poliovirus type 3 antigen (formaldehyde inactivated) - unii:459rom8m9m) - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) 25 [iu] in 0.5 ml - a single dose of kinrix is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (dtap) vaccine series and the fourth dose in the inactivated poliovirus vaccine (ipv) series in children aged 4 through 6 years (prior to the seventh birthday) whose previous dtap vaccine doses have been with infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) and/or pediarix [diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis b (recombinant) and inactivated poliovirus vaccine] for the first 3 doses and infanrix for the fourth dose. severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, pertussis- or poliovirus-containing vaccine, or to any component of kinrix, including neomycin and polymyxin b, is a contraindication to administration of kinrix [see description (11)] . because of the uncertainty as to which component of the vaccine might be responsible, no further vaccination with any of these components should be given. alternatively, such individuals may be referred to an allergist for evaluation if immunization with any of these components is considered. encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, including kinrix. progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy, is a contraindication to administration of any pertussis-containing vaccine, including kinrix. pertussis vaccine should not be administered to individuals with such conditions until a treatment regimen has been established and the condition has stabilized. safety and effectiveness of kinrix in children younger than 4 years and children aged 7 to 16 years have not been evaluated. kinrix is not approved for use in persons in these age groups.

Kanada - angličtina - Health Canada

sanofi pasteur limited - fimbriae; pertactin; diphtheria toxoid; tetanus toxoid; pertussis toxoid; filamentous haemagglutinin - suspension - 5mcg; 3mcg; 15lf; 5lf; 20mcg; 20mcg - fimbriae 5mcg; pertactin 3mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; pertussis toxoid 20mcg; filamentous haemagglutinin 20mcg - toxoids

Kanada - angličtina - Health Canada

sanofi pasteur limited - pertactin; fimbriae; filamentous haemagglutinin; pertussis toxoid; tetanus toxoid; diphtheria toxoid - suspension - 3mcg; 5mcg; 5mcg; 10mcg; 5lf; 15lf - pertactin 3mcg; fimbriae 5mcg; filamentous haemagglutinin 5mcg; pertussis toxoid 10mcg; tetanus toxoid 5lf; diphtheria toxoid 15lf - toxoids

Kanada - angličtina - Health Canada

sanofi pasteur limited - filamentous haemagglutinin; pertussis toxoid; pertactin; diphtheria toxoid; tetanus toxoid; fimbriae types 2 and 3 (fim) - suspension - 5mcg; 2.5mcg; 3mcg; 2lf; 5lf; 5mcg - filamentous haemagglutinin 5mcg; pertussis toxoid 2.5mcg; pertactin 3mcg; diphtheria toxoid 2lf; tetanus toxoid 5lf; fimbriae types 2 and 3 (fim) 5mcg - toxoids

Izrael - angličtina - Ministry of Health

medici medical ltd, israel - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); pertactin (prn); pertussis toxoid vaccine; poliovirus type 1; poliovirus type 2; poliovirus type 3; prp of haemophilus infl. type b; tetanus toxoid - suspension for injection - pertactin (prn) 3 mcg ml; diphtheria toxoid 15 lf ml; tetanus toxoid 5 lf ml; pertussis toxoid vaccine 20 mcg ml; filamentous haemagglutinin (fha) 20 mcg ml; fimbrae tupes 2 + 3 (fim) 5 mcg ml; poliovirus type 1 40 du ml; poliovirus type 2 8 du ml; poliovirus type 3 32 du ml; prp of haemophilus infl. type b 10 mcg ml - bacterial and viral vaccines, combined - pediacel is indicated for immunization of children at or above the age of 2 months and as a booster in children up to their 7th birthday against diphtheria, tetanus, whooping cough, poliomyelitis and invasive haemophilus influenzae type b disease. in infants, three infectons are to be given intramuscularly at 2, 4 and 6 months of age followed by a booster at 18 months of age. children who have had pertusis, tetanus, diphtheria or haemophilus influenzae type b invasive disease should still be immunized since these clinical infections do not always confer immunity. children who have had natural pertussis can continue to receive pertussis - containing vaccines. human immunodeficiency virus (hiv) infected persons hiv- infected individuals, both asymptomatic and symptomatic, should be immunized with pediacel vaccine according to standard schedules.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - tetanus toxoid, quantity: 20 lfu/ml; poliovirus, quantity: 80 agu/ml; pertussis filamentous haemagglutinin, quantity: 50 microgram/ml; poliovirus, quantity: 16 agu/ml; pertactin, quantity: 16 microgram/ml; poliovirus, quantity: 64 agu/ml; pertussis toxoid, quantity: 50 microgram/ml; diphtheria toxoid, quantity: 50 lfu/ml - injection, solution - excipient ingredients: aluminium hydroxide hydrate; water for injections; neomycin sulfate; polymyxin b sulfate; sodium chloride; glucose monohydrate; ascorbic acid; polysorbate 80; calcium chloride dihydrate; ferric nitrate nonahydrate; potassium chloride; magnesium sulfate heptahydrate; monobasic potassium phosphate; dibasic sodium phosphate; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine phosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride monohydrate; sodium hypoxanthine; ribose; sodium acetate; thymine; uracil; sodium xanthine; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; isoleucine; hydroxyproline; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; dl-threonine; dl-tryptophan; tyrosine disodium; dl-valine; biotin; ergocalciferol; calcium pantothenate; choline chloride; folic acid; inositol; menadione; nicotinic acid; nicotinamide; aminobenzoic acid; pyridoxal hydrochloride; pyridoxine hydrochloride; riboflavine; thiamine hydrochloride; retinol acetate; dl-alpha-tocopheryl phosphate disodium - 1. infanrix-ipv is indicated for use in a three dose primary schedule for immunisation of infants from 6 weeks of age and over, against diphtheria, tetanus, pertussis and poliomyelitis. infanrix-ipv is also indicated as a single booster dose for children, up to and including 6 years of age, who have previously been immunised against diphthereia, tetanus, pertussis and polio.